Sarepta Therapeutics, Inc. — fact timeline

Sarepta Therapeutics, Inc. shareholders approved Ratification of KPMG as the Company's Independent Registered Public Accounting Firm at the 2026-06-04 meeting.

“Proposal 5: Ratification of KPMG as the Company ’s Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2026. The results of the vote were as follows: For Against Abstain 79,907,368 2,110,136 291,784”

Sarepta Therapeutics, Inc. shareholders approved Approval of the Company's 2026 Employee Stock Purchase Plan at the 2026-06-04 meeting.

“Proposal 4: Approval of the Company ’s 2026 Employee Stock Purchase Plan The stockholders approved the 2026 ESPP. The results of the vote were as follows: For Against Abstain Broker Non-Votes 67,098,699 532,525 61,783 14,616,281”

Sarepta Therapeutics, Inc. shareholders approved Approval of the Company's 2026 Equity Incentive Plan at the 2026-06-04 meeting.

“Proposal 3: Approval of the Company ’s 2026 Equity Incentive Plan The stockholders approved the 2026 Plan. The results of the vote were as follows: For Against Abstain Broker Non-Votes 63,233,193 4,395,283 64,531 14,616,281”

Sarepta Therapeutics, Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-04 meeting.

“Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for 2025. The results of the advisory vote were as follows: For Against Abstain Broker Non-Votes 45,185,398 22,373,065 134,544 14,616,281”

Sarepta Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.

“Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company’s board of directors as members of Class I for a term of two years. The results of the vote were as follows: Name of Nominee For Against Abstain Broker Non-Votes Douglas S. Ingram 66,812,593 827,973 52,441 14,616,281 Hans Wigzell, M.D., Ph.D. 56,984,756 10,663,180 45,071 14,616,281 Kathryn J. Boor, Ph.D. 63,915,239 3,722,626 55,142 14,616,281 Michael Chambers 65,892,431 1,752,077 48,499 14,616,281 Deirdre Connelly 53,419,881 14,213,242 59,884 14,616,281”

Sarepta Therapeutics, Inc. reported first quarter 2026 results: revenue $330.5 million, net income $331.0 million, EPS $2.88. Guidance reaffirmed.

“Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments – Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues – Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026, respectively”

Sarepta Therapeutics, Inc. entered into First Supplemental Indenture with U.S. Bank Trust Company, National Association (effective 2025-12-18).

“the First Supplemental Indenture (the “First Supplemental Indenture”), dated as of December 18, 2025, each between the Company and U.S. Bank Trust Company, National Association, as trustee”

Sarepta Therapeutics, Inc. entered into Exchange Agreements with certain holders of its 1.25% Convertible Senior Notes due 2027 valued at approximately $291.4 million in aggregate principal amount of Existing Convertible Notes (effective 2025-12-10).

“on December 10, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”)”

Sarepta Therapeutics, Inc. incurred convertible notes of approximately $291.4 million with certain holders (including Michael A. Chambers Living Trust) at 4.875% maturing due 2030.

“the holders party thereto agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”) and (ii) an aggregate of approximately $31.6 million in cash.”

Sarepta Therapeutics, Inc. issued approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 of convertible note to certain holders of its 1.25% Convertible Senior Notes due 2027, including the Michael A. Chambers Living Trust for approximately $291.4 million in aggregate principal amount of Existing Convertible Notes and approximately $31.6 million in cash.

“a member of the Company’s board of directors. Under the terms of the Exchange Agreements, the holders party thereto have agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due”

Sarepta Therapeutics, Inc. incurred convertible notes of $602.0 million in aggregate principal amount with U.S. Bank Trust Company, National Association at 4.875% maturing September 1, 2030.

“party thereto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) $602.0 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”), (ii) an aggregate of 5,851,693 shares of the Company’s common stock, par”

Sarepta Therapeutics, Inc. announced a restructuring with charges of between approximately $32 million and $37 million (approximately 36% of the Company's workforce).

“on July 14, 2025, the Board of Directors of the Company (the “Board”) approved a reduction in force, representing approximately 36% of the Company’s workforce. As a result of this reduction in force, the Company estimates that it will record a one-time charge in the third quarter of 2025 related to employee termination benefits, including severance, between approximately $32 million and $37 million”

Sarepta Therapeutics, Inc. incurred revolving credit of $600 million with JPMorgan Chase Bank, N.A. at Adjusted SOFR plus a margin of 1.125% to 1.75% per annum maturing five years from the Closing Date.

“The Credit Agreement provides for a five-year, $600 million senior secured revolving credit facility”

Cristin Rothfuss was appointed as Executive Vice President, General Counsel at Sarepta Therapeutics, Inc..

“Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.”

Ryan Brown resigned as Executive Vice President, Chief General Counsel at Sarepta Therapeutics, Inc..

“Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.”

Deirdre Connelly was appointed as Director at Sarepta Therapeutics, Inc..

“On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.”

Sarepta Therapeutics, Inc. reported the year ended December 31, 2023 results: revenue $1.145 billion.

“the Company disclosed its (unaudited) cash position of approximately $1.7 billion as of December 31, 2023, and that the Company generated approximately $1.145 billion in total net product revenue (unaudited) in the year ended December 31, 2023”

Sarepta Therapeutics, Inc. shareholders approved Ratification of KPMG as the Company’s Independent Registered Public Accounting Firm at the 2023-06-08 meeting.

“Proposal 6: Ratification of KPMG as the Company’s Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2023. The results of the vote were as follows: For Against Abstain 80,401,023 1,747,340 62,851”

Sarepta Therapeutics, Inc. shareholders approved Advisory Vote on whether an advisory vote on executive compensation should be held every one, two or three years at the 2023-06-08 meeting.

“Proposal 5: Advisory Vote on whether an advisory vote on executive compensation should be held every one, two or three years The stockholders approved, on an advisory basis, the frequency of every one year for an advisory vote on executive compensation. The results of the advisory vote were as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 73,036,748 68,609 617,055 66,930 8,421,872”

Sarepta Therapeutics, Inc. shareholders approved Amendment to the Company’s Amended and Restated 2013 Employee Stock Purchase Plan at the 2023-06-08 meeting.

“Proposal 4: Amendment to the Company’s Amended and Restated 2013 Employee Stock Purchase Plan The stockholders approved the 2016 ESPP Amendment. The results of the vote were as follows: For Against Abstain Broker Non-Votes 73,433,804 332,148 23,390 8,421,872”

Sarepta Therapeutics, Inc. shareholders approved Amendment to the Company’s 2018 Equity Incentive Plan at the 2023-06-08 meeting.

“Proposal 3: Amendment to the Company’s 2018 Equity Incentive Plan The stockholders approved the 2018 Plan Amendment. The results of the vote were as follows: For Against Abstain Broker Non-Votes 65,720,789 8,039,982 28,571 8,421,872”

Sarepta Therapeutics, Inc. shareholders rejected Advisory Vote to Approve Named Executive Officer Compensation at the 2023-06-08 meeting.

“Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders did not approve, on an advisory basis, the compensation of the Company’s named executive officers for 2022. The results of the advisory vote were as follows: For Against Abstain Broker Non-Votes 20,368,530 52,772,697 648,115 8,421,872”

Sarepta Therapeutics, Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.

“Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company’s board of directors as members of Class II for a term of two years. The results of the vote were as follows: Name of Nominee For Against Abstain Broker Non- Votes Richard J. Barry 53,491,803 20,272,569 24,970 8,421,872 M. Kathleen Behrens, Ph.D. 63,663,186 10,095,019 31,137 8,421,872 Stephen L. Mayo, Ph.D. 69,343,149 4,421,653 24,540 8,421,872 Claude Nicaise, M.D. 61,567,590 12,196,029 25,723 8,421,872”

Sarepta Therapeutics, Inc. reported year ended December 31, 2022 results: revenue approximately $843.3 million.

“expects total net product revenue (unaudited) for the year ended December 31, 2022 to be approximately $843.3 million”

Sarepta Therapeutics, Inc. reported fourth quarter ended December 31, 2022 results: revenue approximately $235.5 million.

“the Company expects total net product revenue (unaudited) for the fourth quarter ended December 31, 2022 to be approximately $235.5 million”

Sarepta Therapeutics, Inc.: Amended and restated bylaws to adopt universal proxy rules and update DGCL provisions, including advance notice requirements for stockholder nominees, adjournment of meetings, and removal of stockholder list requirement (effective 2022-12-09).

“On December 9, 2022, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) approved the Second Amended and Restated Bylaws (the “Amended Bylaws”), effective immediately, with such amendments including advance notice provisions to address the adoption by the Securities and Exchange Commission (the “SEC”) of “universal proxy” rules and other updates to reflect amendments to the Delaware General Corporation Law (the “DGCL”) regarding notice of adjourned stockholder meetings and eliminating the requirement of having a stockholder list available at a stockholder meeting, which amendments became effective in August 2022.”

Bilal Arif was appointed as Chief Technical Operations Officer at Sarepta Therapeutics, Inc..

“On October 31, 2022, the Board appointed Bilal Arif, the Company’s Senior Vice President, Strategy and Operations, as the Company’s Chief Technical Operations Officer, effective as of December 31, 2022 and upon Mr. Ciambrone’s retirement.”

William F. Ciambrone resigned as Executive Vice President, Technical Operations at Sarepta Therapeutics, Inc..

“On October 31, 2022, William F. Ciambrone informed Sarepta Therapeutics, Inc. (the “Company”) of his resignation from his position as the Company’s Executive Vice President, Technical Operations, effective as of December 31, 2022.”

Mary Ann Gray departed as director at Sarepta Therapeutics, Inc..

“Mary Ann Gray, Ph.D., informed the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) that she has elected to not stand for re-election and will complete her term on the Board at the conclusion of the Company’s 2022 annual meeting of stockholders.”

Gilmore O'Neill resigned as other_named_officer at Sarepta Therapeutics, Inc..

“On November 15, 2021, the Company and Gilmore O’Neill, M.B., M.M.Sc. mutually agreed to end Dr. O'Neill's employment with the Company, effective as of November 30, 2021”

Louise Rodino-Klapac changed role as Head of R&D, Chief Scientific Officer at Sarepta Therapeutics, Inc..

“On November 16, 2021, Louise Rodino-Klapac, Ph.D., the Company's Chief Scientific Officer, was promoted to Head of R&D, Chief Scientific Officer.”

Stephen L. Mayo was appointed as Director at Sarepta Therapeutics, Inc..

“On November 16, 2021, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the "Company") appointed Stephen L. Mayo, Ph.D. as a director of the Company, effective as of November 16, 2021.”